CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 134 enrolled
Drug / intervention
AZD2423 +2 moredrug
Likely dose
AZD2423 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01201317
NCT01201317Phase 2Completed
CompareCT.gov

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo

AstraZeneca·interventional·Posted Sep 14, 2010·Updated Apr 25, 2014

In Brief

A Phase 2 clinical trial evaluating AZD2423 and Placebo for Neuropathic Pain. Completed, enrolled 134 participants across 20 sites in 2 countries.

Detailed Summary

A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 14, 2010
Enrollment StartSep 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.8 years ago

Interventions

AZD2423drug

20 mg tablet

AZD2423drug

150 mg tablet

Placebodrug

Placebo